Company News2026-06-22

TJ Biopharma Announces NMPA Acceptance of Second BLA for Efmedaglutide Alfa in Type 2 Diabetes

Company News2026-04-20

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region

Company News2025-10-14

TJ Biopharma Announces NMPA Acceptance of BLA for Efmedaglutide Alfa in Obesity

Company News2025-04-15

TJ Biopharma Announces Completion of Patient Enrollment in Phase 2 Clinical Study of Uliledlimab for NSCLC

Company News2025-04-07

TJ Biopharma Joins Biogen-Sponsored Phase 3 Multi-Regional Clinical Trials of Felzartamab in IgAN and PMN

Company News2025-01-10

TJ Biopharma Announces NMPA Acceptance of BLA for Felzartamab in Multiple Myeloma

Company News2024-12-09

TJ Biopharma and Jumpcan Jointly Announce China NMPA Acceptance of BLA for Eftansomatropin Alfa

Company News2024-09-25

TJ Biopharma and Sanofi Enter into Strategic Partnership for Differentiated CD73 Therapy in Greater China

Company News2024-09-20

TJ Biopharma’s Plonmarlimab Granted Breakthrough Therapy Designation in China

• 1
• 2